Kabi Decries ‘Broken Record’ Query As US Tocilizumab Wait Continues
German Firm Received Setback Earlier This Year; First Mover In Europe
Fresenius Kabi continues to feel confident “that we’re going to be pretty much first to market” for its Tyenne proposed biosimilar to Actemra in the US.
